On August 31, Tempus AI fell 5.29% in regular trading, trading at $60.77/share, with turnover of approximately $70.67 million. The decline comes amid persistent selling pressure tied to insider activity and bearish derivatives positioning.

CEO and Chairman Eric Lefkofsky has been conducting consecutive large-scale share disposals. A Form 144 filed on August 26 revealed plans to sell 250,000 shares of Class A common stock through J.P. Morgan Securities, valued at approximately $16.54 million, under a Rule 10b5-1 trading plan adopted in March. This follows a late-July sale of roughly 249,000 shares in the $40.79–$43.13 range. Meanwhile, the options market has shown a concentrated bearish tilt, with a $1.06 million far-dated out-of-the-money call sold and out-of-the-money puts purchased simultaneously, signaling institutional caution on upside potential.

Despite recent positive catalysts — including FDA 510(k) clearance for its AI-enabled pulmonary hypertension detection device and a Q2 earnings beat with adjusted EPS of -$0.04 versus the -$0.14 estimate on revenue of $382.5 million — sustained executive selling and bearish derivatives positioning continue to weigh on near-term sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)